新基因HA117全长cDNA克隆及其耐药功能的实验研究
|
摘要
目的
应用组织芯片结合原位杂交的方法筛选出HA117基因组织表达谱。然后以组织表达谱筛选出的高表达HA117基因的肾脏组织为模板,通过RACE的方法克隆基因全长cDNA,进一步应用重组腺病毒介导的方法获得高表达HA117基因的K562、Jurkat细胞,初步研究HA117基因对K562、Jurkat细胞的多药耐药(MDR)功能。
方法
1组织表达谱筛选,选取石蜡包埋的31例常见肿瘤组织标本制和17例癌旁正常组织制作组织芯片,应用mRNA原位杂交技术检测HA117 mRNA在组织芯片各种组织中的表达情况;
2组织表达谱结果提示肾脏组织高表达HA117基因,收集并提取肾脏组织总mRNA,首先应用RT-PCR方法验证HA117基因在肾脏组织表达情况;然后在高表达HA117基因肾脏组织中,根据已获得的已知HA117基因序列为模板设计特异引物,通过RACE技术克隆HA117基因全长cDNA序列;
3构建携带新基因HA117全长cDNA序列的重组腺病毒,酶切质粒载体pAdTrack-CMV和目的基因HA117后,用T4DNA连接酶将载体和目的基因定向克隆连接,然后筛选和鉴定含目的基因HA117的重组质粒pAdTrack- HA117。将筛选正确的质粒pAdTrack- HA117导入已制备的腺病毒同源骨架质粒BJ-Adeasy中,产生腺病毒质粒Adeasy- HA117,进一步酶切鉴定得到的重组腺病毒质粒Adeasy- HA117。脂质体介导的方法将Adeasy- HA117转染入产病毒包装细胞HEK 293,通过乒乓感染,收获高滴度Ad5- HA117重组腺病毒;并用RT-PCR方法验证,HA117基因在重组腺并毒Ad5- HA117感染的HEK293细胞的表达情况;
4重组腺病毒Ad5- HA117体外感染K562、Jurkat细胞,将重组腺病毒Ad5- HA117体外感染K562、Jurkat细胞,应用流式细胞术及RT-PCR方法检测感染后的K562细胞HA117表达情况;
5检测感染重组腺病毒Ad5- HA117使HA117基因高表达后白血病细胞耐药性改变:实验分四组:K562细胞组,K562/ Ad5- HA117细胞组, K562/ Ad5-GFP细胞组, K562/ Ad5-mdr1细胞组,Jurkat细胞分组同K562。通过对细胞活性、细胞形态学及MTT法抗癌药物敏感实验,柔红霉素排泄实验等检测HA117基因高表达前后细胞形态及耐药性的变化,初步研究HA117基因的耐药功能及耐药机制。
结果
1新基因HA117 mRNA在人体癌旁正常组织和良性肿瘤、恶性肿瘤组织中均有表达,恶性肿瘤组织中表达阳性率高于良性肿瘤及癌旁正常组织中表达阳性率(P>0.5)。在鳞癌和腺癌中的阳性表达率分别是16.67%和61.54%,腺癌中的表达高于鳞癌(P<0.05)。有转移的癌组织中HA117 mRNA的表达率高达70%,明显高于非转移型肿瘤组织的20%(P<0.05) ;
2首先采用RT-PCR方法验证了HA117基因在肾脏组织中高表达。HA117基因的3′RACE PCR产物大小在400bp左右, 5′以RACE PCR产物大小在950bp左右,将HA117基因3′RACE序列、5’RACE扩增序列与己知的HA117基因序列拼接后,得到1110 bp的全长cDNA序列;
3经酶切鉴定成功构建腺病毒重组质粒Ad5- HA117,重组腺病毒Ad5- HA117成功转染包装细胞,在细胞内得到良好的表达,并在包装细胞中迅速扩增,获得高滴度的重组腺病毒。收获的病毒感染液滴度达1.5×1011pfu/ml;RT-PCR方法证实外源性HA117基因在感染HEK293细胞基因组中功能性表达;
4重组腺病毒Ad5-HA117成功将外源性HA117基因导入K562、Jurkat细胞,转染48小时后发现随着感染复数的增加,病毒对K562、Jurkat细胞的感染率也增加, MOI值为100时细胞的存活率和感染率均较好,转染率分别可以达到39.72%、17.10%;RT-PCR方法证实外源性HA117基因在转染K562、Jurkat细胞基因组中功能性表达;
5转染HA117基因的K562、Jurkat细胞对VCR、AD5M、Vp-16、DNR、MMC、CTX药物的耐药性均比低表达HA117基因未转染的k562、Jurkat细胞增高,分别增高2~7倍(P<0.05或0.01),转染空载体组细胞耐药性跟未转染组的k562、Jurkat细胞相比无显著差异(P>0.05);感染Ad5-HA117组细胞与感染Ad5-mdr1组相比,耐药性无显著差异(P>0.05)。转染HA117基因的使其高表达后的K562、Jurkat细胞,与转染了MDR1基因的细胞组柔红霉素排除实验结果显示,感染Ad5-HA117组细胞未见有明显的药物外排泵功能。
结论
1初步证实HA117基因,在人体癌旁正常组织和良性肿瘤、恶性肿瘤组织中均有表达,恶性肿瘤组织中表达阳性率高于良性肿瘤及癌旁正常组织中表达阳性率。HA117表达阳性率可能与恶性肿瘤的组织学类型及是否为转移瘤有关;
2肾脏组织中高表达HA117基因,采用RACE法从肾脏组织中成功克隆得到了HA117基因全长cDNA序列,为全长1110bp;
3应用分子生物学方法构建了HA117重组腺病毒Ad5- HA117。通过荧光显微镜证实,重组腺病毒Ad5- HA117成功转染包装细胞,在细胞内得到良好的表达,获得高滴度的重组腺病毒。证实外源性HA117基因在感染的HEK293细胞有效表达;
4通过腺病毒载体可在体外将外源性HA117基因有效的转K562、Jurkat细胞中,转染的HA117基因能在靶细胞中表达;
5初步证实HA117基因具有多药耐药功能;其多药耐药功能可能不是遵循mdr1经典的药物外排泵机制。
Objective
To select spectra of HA117 gene expressing with tissue chip combined with in-situ hybridization. To full-length cDNA seguence of HA117 gene, through RACE in renal tissue with expressing HA117 gene highly according to expression spectra of HA117 gene. To obtain K562 cells and Jurkat cells expressed HA117 gene highly with recombinant adenovirus mediated, and to study multi-drug resistant fouction of HA117 gene.
Methods
1 Selection of tissue spectra selected 31cases of malignant tumor and 17 cases of normal tissues to make tissue chip, detected the HA117 gene expression in every kinds of tissues of tissue chip with mRNA in-situ hybridization.
2 Clone of total HA117 gene sequence renal tissue had a high HA117 gene expression on bais of tissue spectra result. So collected the renal tissue samples and extracted their total mRNA. Firstly, Validated the HA117 gene expression in renal tissue with RT-PCR; Then using total HA117 gene sequence which had been konwn as templete, designed idio-primers and cloned total cDNA sequence of HA117 gene through RACE in renal tissue expressing HA117 highly.
3 Construction of recombined adenovirus taking alone total cDNA sequence of HA117 gene After cut plasmid vector pAdTrack-CMV and HA117 gene with restricted enzyme, linked vector and HA117 gene with T4 DNA ligase. Then selected and validated the recombined plasimid pAdTrack- HA117 containing HA117 gene. Transducted the plasimid pAdTrack- HA117 which had been validated to be correct into adenoviral homologous frame plasimid BJ-Adeasy prepared to produce adenoviral plasimid Adeasy-HA117. The recombined adenoviral plasimid Adeasy-HA117 was verified with enzyme cutting. Transfected Adeasy-HA117 into virus-producing incasing cells HEK293 with liposome mediated, and gained recombined adenoviral Ad5-HA117 with high titer using ping-pong infection. Verified the HA117 gene expression in HEK293 cells which was infected recombined adenoviral Ad5-HA117 with RT-PCR;
4 Recomined adenovial Ad5-HA117 infected K562 cells and Jurkat cells in vitro: K562 cells and Jurkat cells were infected Ad5-HA117 in vitro. Detected the HA117 expression in K562 cells using flow cytometry and RT-PCR before and after infected;
5 Detecting the drug-resistant change of highly HA117 gene expressing leukemia cells because of being infected Ad5-HA117. In expreiments, cells were classed into four groups: K562 cells group, K562/Ad5-HA117 group, K562/Ad5-GFP group and K562/Ad5-mdr1 group. Groups of Jurkat cells were like to K562 cells’。Studied the drug-resistant fouction and mechanism of HA117 gene through detecting the cytoactivty, cytomorph , anticancer drugs sensitive experiment with MTT and excreting daunorubicin experiment before and after HA117 highly expressed in experimental cells.
Results
1 The new gene HA117 mRNA expressed in normal tissues near malignancy, benign tumor and malignancy. The positive expression rate of malignacy was higher than benign tumor and normal tissues near malignancy(p>0.05). The positive expression rate of squamous carcinoma was 61.54% and higher than adencarcinoma’s 16.67%(p<0.05). The positive expression rate of metastatic malignancy tissue was 70%, obviously higher than non-metastatic malignancy’s 20% (p<0.05).
2 Products of HA117 gene’s 3′RACE PCR and 5′RACE PCR were about 400bp and about 950bp respectivly. The full-length cDNA sequence which was 1110bp was obtained after spliced HA117gene’s 3′RACE, sequence and 5’RACE sequence, with HA117 sequenc which had been konwn.
3 The recombined adenoviral plasimid was constructed successfly per enzyme cutting. Ad5-HA117 was infected in succeed and expressed well in cells incasing cells. After quicly amplified in incasing cells, recombined adenovirus Ad5-HA117 with high tite was gained. The tite of adenvirus solution obtained reached to 1.5×1011pfu/ml.
4 Exogenous HA117 gene was transfected into K562 cells and Jurkat cells with recombined adenovirus Ad5-HA117. After transfected 48 hours, with infecting plural increasing, the infection rates of adenovirus to K562 cells and Jurkat cells were raising too. When MOI was 100, both infected cells’survival rate and infection rate were fairly well. The infection rates of K562 cells and Jurkat cells can reach to 39.72% and 17.10% respectivly
5 Resistance to VCR、AD5M、Vp-16、DNR、MMC、CTX of K562 cells and Jurkat cells which were transfected in HA117 gene was higher 2-7 times(P<0.05 or p<0.01) than the drug-resisrance of untransfected K562 cells and Jurkat cells which had negative HA117 gene expression.Compare with cells in uninfected group, the transfected blank vector cells’drugresistance had no significant deviation(p>0.05). Compare with cells in infected Ad5-mdr1 group, drugresistance of cells in transfected Ad5-HA117 group had no significant deciation (p>0.05). The DNR extrusion test results of cells transfected in HA117 gene and cells transfected in mdr1 gene indicated that cells transfected in HA117 were no conspicuous drug-excreting pumping function.
conclusions
1 Tentative confirmed that HA117 gene may express in normal tissue near carcinoma, benign tumor tissue and malignancy tissue. The positive expression rate of malignacy was higher than the positive expression rate of benign tumor and normal tissues near malignancy. Whether the positive expression is relate to the histological type and metastasis of malignancy.The genes may be an index in monitoring the status and evaluating the prognosis of the malignant tumor.
2 Full-length of HA117 gene sequence were cloned successfully in renal tissue with RACE, and it’s full-length is 1110bp
3 Constructed the recombined adenovirus Ad-HA117 using Adeasy-1 adenovirus vector system with molecular biological mathod. Validated with GFP expression under fluorescence microscope , Ad5-HA117 was transfected successfully and expressed well in incasing cells. After amplified in incasing cells quickly, the recombined adenovirus with high titer was gained.
4 The exogenous HA117 gene could be transferred into K562 and Jurkat cells efficiently by vecter of adenovirus in vitro, and the stable and efficient expression of HA117 gene in cells could be tested. These data provide a foundation and evidence for the further research on multi-drug resistant of HA117 in vitro .
5 Multi-drug resistant function of HA117 gene was verified, Mechanism of Multi-drug resistant function may not follow the classic excretion pump of mdr1.
应用组织芯片结合原位杂交的方法筛选出HA117基因组织表达谱。然后以组织表达谱筛选出的高表达HA117基因的肾脏组织为模板,通过RACE的方法克隆基因全长cDNA,进一步应用重组腺病毒介导的方法获得高表达HA117基因的K562、Jurkat细胞,初步研究HA117基因对K562、Jurkat细胞的多药耐药(MDR)功能。
方法
1组织表达谱筛选,选取石蜡包埋的31例常见肿瘤组织标本制和17例癌旁正常组织制作组织芯片,应用mRNA原位杂交技术检测HA117 mRNA在组织芯片各种组织中的表达情况;
2组织表达谱结果提示肾脏组织高表达HA117基因,收集并提取肾脏组织总mRNA,首先应用RT-PCR方法验证HA117基因在肾脏组织表达情况;然后在高表达HA117基因肾脏组织中,根据已获得的已知HA117基因序列为模板设计特异引物,通过RACE技术克隆HA117基因全长cDNA序列;
3构建携带新基因HA117全长cDNA序列的重组腺病毒,酶切质粒载体pAdTrack-CMV和目的基因HA117后,用T4DNA连接酶将载体和目的基因定向克隆连接,然后筛选和鉴定含目的基因HA117的重组质粒pAdTrack- HA117。将筛选正确的质粒pAdTrack- HA117导入已制备的腺病毒同源骨架质粒BJ-Adeasy中,产生腺病毒质粒Adeasy- HA117,进一步酶切鉴定得到的重组腺病毒质粒Adeasy- HA117。脂质体介导的方法将Adeasy- HA117转染入产病毒包装细胞HEK 293,通过乒乓感染,收获高滴度Ad5- HA117重组腺病毒;并用RT-PCR方法验证,HA117基因在重组腺并毒Ad5- HA117感染的HEK293细胞的表达情况;
4重组腺病毒Ad5- HA117体外感染K562、Jurkat细胞,将重组腺病毒Ad5- HA117体外感染K562、Jurkat细胞,应用流式细胞术及RT-PCR方法检测感染后的K562细胞HA117表达情况;
5检测感染重组腺病毒Ad5- HA117使HA117基因高表达后白血病细胞耐药性改变:实验分四组:K562细胞组,K562/ Ad5- HA117细胞组, K562/ Ad5-GFP细胞组, K562/ Ad5-mdr1细胞组,Jurkat细胞分组同K562。通过对细胞活性、细胞形态学及MTT法抗癌药物敏感实验,柔红霉素排泄实验等检测HA117基因高表达前后细胞形态及耐药性的变化,初步研究HA117基因的耐药功能及耐药机制。
结果
1新基因HA117 mRNA在人体癌旁正常组织和良性肿瘤、恶性肿瘤组织中均有表达,恶性肿瘤组织中表达阳性率高于良性肿瘤及癌旁正常组织中表达阳性率(P>0.5)。在鳞癌和腺癌中的阳性表达率分别是16.67%和61.54%,腺癌中的表达高于鳞癌(P<0.05)。有转移的癌组织中HA117 mRNA的表达率高达70%,明显高于非转移型肿瘤组织的20%(P<0.05) ;
2首先采用RT-PCR方法验证了HA117基因在肾脏组织中高表达。HA117基因的3′RACE PCR产物大小在400bp左右, 5′以RACE PCR产物大小在950bp左右,将HA117基因3′RACE序列、5’RACE扩增序列与己知的HA117基因序列拼接后,得到1110 bp的全长cDNA序列;
3经酶切鉴定成功构建腺病毒重组质粒Ad5- HA117,重组腺病毒Ad5- HA117成功转染包装细胞,在细胞内得到良好的表达,并在包装细胞中迅速扩增,获得高滴度的重组腺病毒。收获的病毒感染液滴度达1.5×1011pfu/ml;RT-PCR方法证实外源性HA117基因在感染HEK293细胞基因组中功能性表达;
4重组腺病毒Ad5-HA117成功将外源性HA117基因导入K562、Jurkat细胞,转染48小时后发现随着感染复数的增加,病毒对K562、Jurkat细胞的感染率也增加, MOI值为100时细胞的存活率和感染率均较好,转染率分别可以达到39.72%、17.10%;RT-PCR方法证实外源性HA117基因在转染K562、Jurkat细胞基因组中功能性表达;
5转染HA117基因的K562、Jurkat细胞对VCR、AD5M、Vp-16、DNR、MMC、CTX药物的耐药性均比低表达HA117基因未转染的k562、Jurkat细胞增高,分别增高2~7倍(P<0.05或0.01),转染空载体组细胞耐药性跟未转染组的k562、Jurkat细胞相比无显著差异(P>0.05);感染Ad5-HA117组细胞与感染Ad5-mdr1组相比,耐药性无显著差异(P>0.05)。转染HA117基因的使其高表达后的K562、Jurkat细胞,与转染了MDR1基因的细胞组柔红霉素排除实验结果显示,感染Ad5-HA117组细胞未见有明显的药物外排泵功能。
结论
1初步证实HA117基因,在人体癌旁正常组织和良性肿瘤、恶性肿瘤组织中均有表达,恶性肿瘤组织中表达阳性率高于良性肿瘤及癌旁正常组织中表达阳性率。HA117表达阳性率可能与恶性肿瘤的组织学类型及是否为转移瘤有关;
2肾脏组织中高表达HA117基因,采用RACE法从肾脏组织中成功克隆得到了HA117基因全长cDNA序列,为全长1110bp;
3应用分子生物学方法构建了HA117重组腺病毒Ad5- HA117。通过荧光显微镜证实,重组腺病毒Ad5- HA117成功转染包装细胞,在细胞内得到良好的表达,获得高滴度的重组腺病毒。证实外源性HA117基因在感染的HEK293细胞有效表达;
4通过腺病毒载体可在体外将外源性HA117基因有效的转K562、Jurkat细胞中,转染的HA117基因能在靶细胞中表达;
5初步证实HA117基因具有多药耐药功能;其多药耐药功能可能不是遵循mdr1经典的药物外排泵机制。
Objective
To select spectra of HA117 gene expressing with tissue chip combined with in-situ hybridization. To full-length cDNA seguence of HA117 gene, through RACE in renal tissue with expressing HA117 gene highly according to expression spectra of HA117 gene. To obtain K562 cells and Jurkat cells expressed HA117 gene highly with recombinant adenovirus mediated, and to study multi-drug resistant fouction of HA117 gene.
Methods
1 Selection of tissue spectra selected 31cases of malignant tumor and 17 cases of normal tissues to make tissue chip, detected the HA117 gene expression in every kinds of tissues of tissue chip with mRNA in-situ hybridization.
2 Clone of total HA117 gene sequence renal tissue had a high HA117 gene expression on bais of tissue spectra result. So collected the renal tissue samples and extracted their total mRNA. Firstly, Validated the HA117 gene expression in renal tissue with RT-PCR; Then using total HA117 gene sequence which had been konwn as templete, designed idio-primers and cloned total cDNA sequence of HA117 gene through RACE in renal tissue expressing HA117 highly.
3 Construction of recombined adenovirus taking alone total cDNA sequence of HA117 gene After cut plasmid vector pAdTrack-CMV and HA117 gene with restricted enzyme, linked vector and HA117 gene with T4 DNA ligase. Then selected and validated the recombined plasimid pAdTrack- HA117 containing HA117 gene. Transducted the plasimid pAdTrack- HA117 which had been validated to be correct into adenoviral homologous frame plasimid BJ-Adeasy prepared to produce adenoviral plasimid Adeasy-HA117. The recombined adenoviral plasimid Adeasy-HA117 was verified with enzyme cutting. Transfected Adeasy-HA117 into virus-producing incasing cells HEK293 with liposome mediated, and gained recombined adenoviral Ad5-HA117 with high titer using ping-pong infection. Verified the HA117 gene expression in HEK293 cells which was infected recombined adenoviral Ad5-HA117 with RT-PCR;
4 Recomined adenovial Ad5-HA117 infected K562 cells and Jurkat cells in vitro: K562 cells and Jurkat cells were infected Ad5-HA117 in vitro. Detected the HA117 expression in K562 cells using flow cytometry and RT-PCR before and after infected;
5 Detecting the drug-resistant change of highly HA117 gene expressing leukemia cells because of being infected Ad5-HA117. In expreiments, cells were classed into four groups: K562 cells group, K562/Ad5-HA117 group, K562/Ad5-GFP group and K562/Ad5-mdr1 group. Groups of Jurkat cells were like to K562 cells’。Studied the drug-resistant fouction and mechanism of HA117 gene through detecting the cytoactivty, cytomorph , anticancer drugs sensitive experiment with MTT and excreting daunorubicin experiment before and after HA117 highly expressed in experimental cells.
Results
1 The new gene HA117 mRNA expressed in normal tissues near malignancy, benign tumor and malignancy. The positive expression rate of malignacy was higher than benign tumor and normal tissues near malignancy(p>0.05). The positive expression rate of squamous carcinoma was 61.54% and higher than adencarcinoma’s 16.67%(p<0.05). The positive expression rate of metastatic malignancy tissue was 70%, obviously higher than non-metastatic malignancy’s 20% (p<0.05).
2 Products of HA117 gene’s 3′RACE PCR and 5′RACE PCR were about 400bp and about 950bp respectivly. The full-length cDNA sequence which was 1110bp was obtained after spliced HA117gene’s 3′RACE, sequence and 5’RACE sequence, with HA117 sequenc which had been konwn.
3 The recombined adenoviral plasimid was constructed successfly per enzyme cutting. Ad5-HA117 was infected in succeed and expressed well in cells incasing cells. After quicly amplified in incasing cells, recombined adenovirus Ad5-HA117 with high tite was gained. The tite of adenvirus solution obtained reached to 1.5×1011pfu/ml.
4 Exogenous HA117 gene was transfected into K562 cells and Jurkat cells with recombined adenovirus Ad5-HA117. After transfected 48 hours, with infecting plural increasing, the infection rates of adenovirus to K562 cells and Jurkat cells were raising too. When MOI was 100, both infected cells’survival rate and infection rate were fairly well. The infection rates of K562 cells and Jurkat cells can reach to 39.72% and 17.10% respectivly
5 Resistance to VCR、AD5M、Vp-16、DNR、MMC、CTX of K562 cells and Jurkat cells which were transfected in HA117 gene was higher 2-7 times(P<0.05 or p<0.01) than the drug-resisrance of untransfected K562 cells and Jurkat cells which had negative HA117 gene expression.Compare with cells in uninfected group, the transfected blank vector cells’drugresistance had no significant deviation(p>0.05). Compare with cells in infected Ad5-mdr1 group, drugresistance of cells in transfected Ad5-HA117 group had no significant deciation (p>0.05). The DNR extrusion test results of cells transfected in HA117 gene and cells transfected in mdr1 gene indicated that cells transfected in HA117 were no conspicuous drug-excreting pumping function.
conclusions
1 Tentative confirmed that HA117 gene may express in normal tissue near carcinoma, benign tumor tissue and malignancy tissue. The positive expression rate of malignacy was higher than the positive expression rate of benign tumor and normal tissues near malignancy. Whether the positive expression is relate to the histological type and metastasis of malignancy.The genes may be an index in monitoring the status and evaluating the prognosis of the malignant tumor.
2 Full-length of HA117 gene sequence were cloned successfully in renal tissue with RACE, and it’s full-length is 1110bp
3 Constructed the recombined adenovirus Ad-HA117 using Adeasy-1 adenovirus vector system with molecular biological mathod. Validated with GFP expression under fluorescence microscope , Ad5-HA117 was transfected successfully and expressed well in incasing cells. After amplified in incasing cells quickly, the recombined adenovirus with high titer was gained.
4 The exogenous HA117 gene could be transferred into K562 and Jurkat cells efficiently by vecter of adenovirus in vitro, and the stable and efficient expression of HA117 gene in cells could be tested. These data provide a foundation and evidence for the further research on multi-drug resistant of HA117 in vitro .
5 Multi-drug resistant function of HA117 gene was verified, Mechanism of Multi-drug resistant function may not follow the classic excretion pump of mdr1.
引文
[1] Hamre MR, Williams J, et al. Early deaths in childhood cancer. Med Pediatr Oncol. 2000;34(5):343-7.
[2]王振义,陈竺主编.肿瘤的诱导分化和凋亡疗法.上海科学技术出版社出版,1998:4-5.
[3] Douer D. New Ad5vances in the treatment of acute promyelocytic leukemia.Int J Hematol ,2002,762:179-87.
[4] Gueddari N, MAd5oulet C, Lefebvre P, et al. Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60).Leuk Res 2000 Jun;24(6):543-8.
[5] Del BinoG, Li X, Traganos F, et al. Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs. Leukemia 1994,8:281-287.
[6] Solary E, Bertrand R, Kohn KW, et al. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.Blood, 1993,81:1359.
[7] Marks DC, Davey MW, Davey RA, et al. Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line. Biochem Pharmacol , 1995 ,50(4):475-480.
[8] Ketley NJ, Allen PD, Kelsey SM, et.al. Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH)2 Vitamin D3,and Granulocyte-Macrophage Colony-Stimulating Factor, Blood, 1997,90 (11): 4578-4587
[9] Ketley NJ, Allen PD, Kelsey SM, et.al. Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints. Leukemia, 2000,14(4):620-628.
[10] Zheng M, Simon R, Kononen J, Sauter G, Mihatsch MJ, Moch H. Analysis of gene expression profiles among 3 epithelial ovarian tumor subtypes using cDNA and tissue microarrays.Ai Zheng 2004; 23: 771-776
[11] Andersen CL, Monni O, Wagner U, Kononen J, Barlund M, Bucher C, Haas P, Nocito A, Bissig H, Sauter G, Kallioniemi A. High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fl uorescence in situ hybridization to tissue microarrays. Am J Pathol 2002; 161: 73-79
[12]付劲蓉刘文励周剑锋等。急性髓系白血病细胞多药耐药相关基因的筛选。华中科技大学学报(医学版)。2005,34(6):659-665.
[13] Kononen J,Bubendorf L,Kallionie mi A,et a1.Tissue microarrays for high-throughput molecular profiling of tumor specimens[J].Nat Med,1998,4:844-847.
[14]周小鸽,张劲松,张小平等。组织芯片团。中华病理学杂志,2002, 31 (2): 70-71.
[15] Battifora H, The multitumor(sauage) tissue block:novel method for immunohistochemical antibody testing[J].Lab Invest, 1986,55:244-248.
[16]韩瑞刚,张建中,黄英武等。肺石蜡包埋组织及新鲜标本组织芯片制备方法学探讨闭。临床实验病理学杂志,2002, 18 (4): 404-408。
[17] Schraml PKononen J,Bubendorf L, et a1.Tissue microarrays for gene amplification surveys in many different tumor types[J].Clin Cancer Res,1999,5:1966-1975.
[18] Schraml PSchmerdtfeger QBurkhalter F, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAKI at llq13,5-q14 as a critical oncogene target in ovarian carcinoma[J].Ammerican J of Pathol, 2003, 163:985-992.
[19] StojAd5inovic A, Hoos A, Nissan A, et al. Parathyroid neoplasm: clinical, histopathological,and tissue microarray-based molecular analysis[J].Hum Pathol, 2003,34(1):54-64.
[20] Freier K, Joos S, Flechtemacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplification in heAd5 and neck squamous cell carcinoma [J].Cancer Res, 2003, 63(6): 1179-1182.
[21] Zaharieva BM, Simon R, Diener PA, et al. High-throughput tissue microarray analysis of llq13 gene amplification (CCND1, FGF3, FGF4, EMSI)in urinary blAd5der cancer[J].J Patho1,2003,201(4):603-608.
[22] Kang JY, Dolled FM, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met,matriptase,and hepatocyte growth factor activator inhibitor 1 in the progression of mole-egative breast cancer[J].Cancer Res,2003, 63(5):1102-1105.
[23]张杰林,方燕,黄必军等,应用组织微阵列技术分析各期鼻咽癌组织P16切.中华病理学杂志,2002,31 (2): 132-1350
[24] Chan JK, Wong CS, Ku WT, et al. Reflections on the use of controls in immunohistochemistry and proposal for application of a multitissue spring-roll control block [J].Ann Diagn Patho1,2000,4(5):329-336.
[25] Packeisen J, Buerger H, Krech R, et al. Tissue microarrays:A new approach for quality control in immunhistochemistry[J].J of Clinical Patho1,2002,55:613-615.
[26] LiH,SunY,KongQY,ZhangKL,Wan gXW ,Chen XY,Wang Q,Liu J.Combination of nucleic acid an d protein isolation with tissue array cons truction:using defined histologic regions in single frozen tissue blocks for multiple research purposes.Int,MofMed 2003;12:299-304
[27] Cui Dx,Zhan g L,Yan XJ,Zhang LX,Xu JR,GuoYH。Jin GQ。Gomez Gt Li Dt Zhao JRt Han FCI Zhang J,Hu JL,Fan DM,Gao HJ.A microarraybasedgastric carcinoma prewarning system .WorldI Gastroenterol 2005;11:1273.1282
[28] Dan HLt Zhang YL。Zhang Yt W ang YDt Lai ZS.Yan g Cui HH,JianⅥ,Geng J,Ding YQ Guo CHI Zhou DY.A novel meth od for preparation of tissue microarray.World I Gastroenterol 2004;10:579.582
[29] Lusis EA,Chicoine MR,Perry A.High throughputscreening of meningioma biomarkers using a tissuemicroarray.,Neurooncol 2005;73:219.223
[30] Sun Y,Li JY,He JS,zhou LX,Chen K.Tissuemicroarray an alysis of multiple gene expression in intestinal metaplasia,dysplasia an d carcinom a of the stom ach.Histopatholo~ 2005:46:5O5_514
[31] Kondoh N,Wakatsuki T,Ryo A,HAd5a A,et al.Identification and characterization genes associated with human hepatocellular carcinogenesis[J].Cancer Re 1999,59(19):4990-4996.
[32] Ueta T,Ikeguchi M,Hirooka Y,et al.Beta-catenin and cyclin D1 expression human hepatocellular carcinoma[J].Oncol Rep,2002,9(6):1197-1203.
[33] Yamamoto S,Tomita Y,Nakamori S,et al.Elevated expression ovalosin-containing protein(p97)in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence[J].J Clin Oncol,2003,21(3):447-452 .
[34] Chuma M,Sakamoto M,Yamazaki K,et al.Expression profiling in multistage hepatocarcinogenesis:identification of HSP70 as a molecular marker of earhepatocellular carcinoma [J].Hepatology,2003,37(1):198-207.
[35] Xu H, Tepper CG, Jones JB, Fernandez CE, Studzinski GP: 1,25-dihydroxyvitamin D3 protects HL-60 cells against apoptosis but down-regulates the expression of the Bcl-2 gene. Exp Cell Res, 1993,209:367.
[36] Del BinoG, Li X, Traganos F, et al. Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs. Leukemia 1994,8:281-287.
[37] Solary E, Bertrand R, Kohn KW, et al. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.Blood, 1993,81:1359.
[38] Marks DC, Davey MW, Davey RA, et al. Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line. Biochem Pharmacol , 1995 ,50(4):475-480.
[39]张开泰,李刚,葛世丽,等.生物素标记文库筛选与cDNA快速终末端扩增技术克隆HRNT-l新基因[J].癌症.2000, 19(9): 939942.
[40] Frohman, M. A., Dush, M. K., Martin, G. R. Rapid production of full-length cDNAsfrom rare transcripts: amplification using a single gene-specific oligonucleotide primer [J]. Proc Natl AcAd5 Sci USA. 1988, 85: 8998-9002.
[41]邬珺超,蒋滢.cDNA末端快速扩增技术的研究进展.氨基酸和生物资源.2003,25(1):2531.
[42] Loh EY, Elliotl JF, Cwila S, et al. Poly-merase chain reaction with single-sided specificity: analysis of T cell receptor d chain[J]. Science. 1989, 243: 217-220.
[43] Ohara O., Dorit R. L., Gilbert W. One-sided poly-merase chain reaction: The amplification of cDNA[J]. Proc Natl AcAd5 Sci USA. 1989, 86: 5673-5677.
[44]李关荣,鲁成,夏庆友,等.cDNA末端快速扩增技术(RACE)的优化与改良.生命科学研究.2003, 7(3):189-197.
[45] Forhman MA,Dush MK,Martin GR.Rapid production of full-length cDNAs from rare transcripts:amplification using a single gene-specific oligonucleotide prime[J].Proc Natl AcAd5 Sci USA,1988,85:8998.
[46] Miller AD5. Human gene therapy comes of age. Nature. 1992 Jun 11; 357(6378): 455-60.
[47] Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem. 1993; 62: 191-217.
[48] Graham, F. L. & Prevec, L. (1991). Methods Mol. Biol. 7, 109 128.
[49] Berkner KL. Development of Ad5enovirus vectors for the expression of heterologous genes. Biotechniques. 1988 Jul-Aug; 6(7): 616-29.
[50] Stewart PL, Fuller SD, Burnett RM. Difference imaging of Ad5enovirus: bridging the resolution gap between X-ray crystallography and electron microscopy[J]. EMBO J. 1993 Jul; 12(7): 2589-99
[51] Rekosh DM, Russell WC. Processing of the precursor to the major core polypeptide of Ad5enovirus type 5 removes a region near the amino terminus[J]. Virology. 1977 Oct 15; 82(2): 513-7
[52] Anderson CW, Young ME, Flint SJ. Characterization of the Ad5enovirus 2 virion protein, mu[J]. Virology. 1989 Oct; 172(2): 506-12
[53] Matthews DA, Russell WC. Ad5enovirus protein-protein interactions: molecular parameters governing the binding of protein VI to hexon and the activation of the Ad5enovirus 23K protease[J]. Gen Virol. 1995 Aug; 76 ( Pt 8): 1959-69
[54] Weber J. Genetic analysis of Ad5enovirus type 2 III. Temperature sensitivity of processing viral proteins[J]. Virol. 1976 Feb; 17(2): 462-71
[55] Webster A, Russell WC, Kemp GD. Characterization of the Ad5enovirus proteinase: development and use of a specific peptide assay[J]. Gen Virol. 1989 Dec; 70 ( Pt 12): 3215-23
[56] Horwitz, M. S. Fields, B. N., Knipe, D. M., Howley, P. M., Chanock, R. M., Melnick, J. L., Monath, T. P., Roizman, B., & Straus, S. E., eds. (1996) in Fields Virology (Lippincott, PhilAd5elphia)
[57] Ballay A, Levrero M, Buendia MA et al. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human Ad5enoviruses[J]. EMBO J. 1985 Dec 30; 4(13B): 3861-5
[58] Rosenfeld MA, Siegfried W, Yoshimura K, et al. Ad5enovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo[J]. Science. 1991 Apr 19; 252(5004): 431-4
[59] Hayashi S,Ieu D,Yamii Y ,et a1.Effect of Ad5enovirus-mediated transfer of the CTI A4 IG gene in hamster-to-rat xenotransplantation.Transplantation,2005,80:494.
[60] Kanerva A,Hemminki A.Ad5enoviruses for treatment of cancer. Ann Med , 2005 , 37:33-43.
[61] Phase 2 breast cancer study shows clinical responses in 90 percent of patients treated with Introgen,s Ad5vexin therapy.Introgen Therapeu- tics,Inc.News Release,2003,6-2.
[62] Douer D. New Ad5vances in the treatment of acute promyelocytic leukemia.Int J Hematol ,2002,762:179-87.
[63] Gueddari N, MAd5oulet C, Lefebvre P, et al. Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60).Leuk Res 2000 Jun;24(6):543-8.
[64] Dam iani D , M ichieli M ,M ichelutti A , et a1.AntibodY binding capacity for evaluation of M DR-related proteins in acute promyelocytic leukemia;Onset versus relapse expression. Cytometry B Clin Cytom ,2004,59(1):4O-45.
[65] Degos L.The history of acute promyelocytic leukamemia.Br J Haematol,2003,122(4):539-553.
[66] Ronan Quere, Aurelie Baudet, Bruno Cassinat,et al. Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood, 2007, 10.1182.
[67] Casale F, D’Angelo V , Ad5deo R, et a1. P-glycoprotein 17O expression and function as an Ad5verse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep.2004, 12(6):1201-1207.
[68] Stromskaya TP.Rybalkina EY.Zabotina TN,et al. Influence of RARa gene on M DR1 expression and P-glycoprotein function in human leukemic cells. Cancer CeIl Int,2005,5:15.
[69] JS Moreb, D Mohuczy, D Muhoczy, et al. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol, 2007; 59(1): 127-36.
[70] Solary E, Bertrand R, Kohn KW, et al. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.Blood, 1993,81:1359.
[71] Marks DC, Davey MW, Davey RA, et al. Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line. Biochem Pharmacol , 1995 ,50(4):475-480.
[72] Palozza P, Serini S, Torsello A, et al. Regulation of cell cycle progression and apoptosis by beta-carotene in undifferentiated and differentiated HL-60 leukemia cells: possible involvement of a redox mechanism. Int J Cancer,2002, 97(5):593-600.
[73] Brown G, Drayson MT, Durham J, et al. HL60 cells halted in G1 or S phase differentiate normally. Exp Cell Res ,2002 ,281(1):28-38.
[74] Ketley NJ, Allen PD, Kelsey SM, et.al. Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH)2 Vitamin D3,and Granulocyte-Macrophage Colony-Stimulating Factor, Blood, 1997,90 (11): 4578-4587.
[1]. Okuno M, Kojima S, Matsushima-Nishiwaki R, et al. Rrtinoids in cancer chemoprevention. Curr Cancer Drug Targets, 2004,4(3): 285-298.
[2]. Candoni A, Damiani D, Michelutti A, et al. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in Ad5ult patients with acute promyelocytic leukemia. Eur J Haematol, 2003,71(1):1-8.
[3]. Ronan Quere, Aurelie Baudet, Bruno Cassinat,et al. Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood, 2007, 109(10): 4450-4460.
[4].王玮,岑建农,李建勇,等,急性白血病中MDR1、MRP和BCL-2表达及其临床意义.中国肿瘤临床, 2003,30(7):470-473.
[5]. Casale F, D’Angelo V, Ad5deo R ,et a1. P-glycoprotein 170 expression and function as an Ad5verse independent prognostic factor in childhood acute lymphoblastic leukemia.Oncol Rep.2004, 12(6):1201-1207.
[6]. Stromskaya TP. Rybalkina EY .Zabotina TN ,et al. Influence of RARa gene on MDR1 expression and P-glycoprotein function in human leukemic cells. Cancer CeIl Int , 2005,5:15.
[7]. Takeshita, A, Shigeno, K, Shinjo K, et al。All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance.Leuk-Lymphoma. 2001 ,42(4): 739-746.
[8]. Galimberti S, Testi R, Guerrini F, et al.: The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia. J Chemother 2003, 15(4): 374-379.
[9]. Van den Heuvel-Eibrink MM, Wiemer EA, Prins A, et al. Increased expression of breast cancer resistance in relapsed or refractory acute myeloid leukemia. Leukemia, 2002, 16(5): 833-839.
[10]. Herman Burger, Hans van Tol, Antonius W. M. et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 2004, 104(9):2940-2942.
[11].任金海,杜行严,郭晓楠,等,急性白血病细胞的乳腺癌耐药蛋白基因表达与化疗耐药的关系.中国实验血液学杂志,2004,12(1):55-58.
[12]. Schaich M, Koch R, Soucek S, et al .A sensitive model for prediction of relapse in Ad5ult acute myeloid leukaemia with t (8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis. Br J Haematol 2004, 125(4): 477-479.
[13]. Avivi, Irit; Rowe, Jacob M。Prognostic factors in acute myeloid leukemia . Current Opinion on Hematology, 2005, 12 (1) :62-67.
[14]. Imaizumi M, Suzuki H, Yoshinari M, et al. Mutations in the E-Dornain of RARαprotein of the PML-RARαchimeric Gene may confer clinicl resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood, 1998, 92(2):374-382.
[15]. Gaboli M, Candini D, Delval, et al. acute promyelocytic leukemia as a model forcross-talk between interferon and retinoic acid phhways: from molecular biology to clinical applications. Leuk lymphoma, 1998 , 30 (1-2): 11-22.
[16]. Huan SY, Yang CH, Chen YC. Arsenic trioxide therapy for ielapsed acute promyelocytic leukemia:an useful salvage therapy. Leuk lymphoma, 2000,38 (3-4) : 283-293.
[17]. Zwiebel JA, New agents for acute promyelocytic leukemia. Leukemia, 2000,14(3): 488-490.
[18]. Ikezoe T, Daar ES, Hisatake J, et al. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood, 2000,96(10): 3553-3559.
[1]. Hocking DC, Kowalski K. A cryptic fragment from fibronectin’s III1 aodule localizes to lipid rafts and stimulates cell growth and contractility. Cell Biol,2002,158(1):175.
[2]. Finnemann S. C. and Silverstein R. L.Differential Roles of CD36 and {alpha}v{beta}5 Integrin in Photoreceptor Phagocytosis by the Retinal Pigment Epithelium.J. Exp. Med, 2001, 194(9): 1289 - 1298.
[3]. Bocquie AA, Potss JR, Pickfored AR, et al. Solution structure of a pair ofmodules from the gelaoin-binding domain of fibronectin. Structure Fold Des, 1999,7(12):1451.
[4]. Huesca M, Sun Q, Peralta R, et al. Synthetic peptide immunogens elicit polyclonal and monoclonal antibodies specific for linear epitopes in the D motifs of Staphylococcus aureus fibronectin-binding protein, which are composed of amino acids that are essential for fibronectin binding. Infect Immum,2000,68 (3):1156.
[5]. Yair Gazitt, Cagla Akay. Mobilization of Myeloma Cells Involves SDF-1/CXCR4 Signaling and Downregulation of VLA-4. Stem Cells, 2004,22(1):65-73.
[6]. Orschell-Traycoff, Anna Jetmore and Edward F. Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34+ cells transplanted into conditioned NOD/SCID recipients.Blood, 2002,99(3): 1585 - 1593.
[7]. Christina H, Diana D, Gunnar M, Jochen G, et al .Expression and Function of Homing-Essential Molecules and Enhanced In Vivo Homing Ability of Human Peripheral Blood-Derived Hematopoietic Progenitor Cells after Stimulation with Stem Cell Factor.Stem cells, 2004,22(7):580-589
[8]. Foguenne J, Huygen S, Greimers R, et al. Modulation of homing properties of primitive progenitor cells generated by ex vivo expansion. Haematologica,2005 ,90(4):445-51.
[9]. Maria A,Hui Wang,Megan Sykes,et al.Role of VLA-4 and VLA-5 in ex vivo maintenance of human and pig hematopoiesis in human stroma-supported long-term cultures.Experimental Hematology,2005,33(1):363-370.
[10]. Shain KH, Dalton WS.Cell Ad5hesion is a key determinant in de novo multidrug resisrance(MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther, 2001,1(1):69-78.
[11]. Holt RU, Baykov V, Ro TB, et al. Human myeloma cells Ad5here to fibronectin in response to hepatocyte growth factor. Haematologica, 2005 ,90(4):479-488..
[12]. Hazlehurst LA, Damiano JS, Buyyksal I, et al. Ad5hesion to fibronectin via betal integrins reglates p27kipl levels andcontributes to cell Ad5hesion mediated drug resistance (CAM-DR). Oncogene, 2000,19(38):4319-4327.
[13]. Landowski TH, Olashaw NE, Agrawal D, et al. Cell Ad5hesion mediated drugresistance (CAM-DR) is associated with activation of NF-kappa B(RelB/p50) in myeloma cells. Oncogene, 2003,22(16):2417-2421.
[14]. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.Leukemia, 2003,17(6):1175-1182.
[15]. de la Fuente MT, Casanova B,Moyano JV, et al. Engagement of alpha4betal integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabne. J Leukoc Biol, 2002,71(3):495-502.
[16]. Matsunaga T, Takemoro N, Sato T, et al. Interaction between leukemic VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med,2003,9(9):1158-1165.
[17]. Chauhan D, G. Li, K. Podar, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.Blood, 2004,103(8): 3158 - 3166.
[18]. Shain KH, Landowski TH, Dalton WS. Ad5hesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistances to CD95 induced apoptosis in hematopoietic cancer cell lines. J Immunol, 2002,17(6):2544-2553.
[19]. Nefedova Y, P. Cheng, M. Alsina, et al. and D.I.GabrilovichInvolvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines.Blood,2004,103(9): 3503 - 3510.
[20]. Heyu Ni , Cecile VD, Sangeetha S, et al. Persistence of platelet thrombus fomation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Inves,2001(8),106:385-392.
[21]. An G, Dong N, Shao B, Zhu M, Ruan C. Preparation and characterization of a single chain antibody fragment of mAb SZ-21 against platelets GPIIIa。Zhonghua Xue Ye Xue Za Zhi, 2002 ,23(9):480-2.
[2]王振义,陈竺主编.肿瘤的诱导分化和凋亡疗法.上海科学技术出版社出版,1998:4-5.
[3] Douer D. New Ad5vances in the treatment of acute promyelocytic leukemia.Int J Hematol ,2002,762:179-87.
[4] Gueddari N, MAd5oulet C, Lefebvre P, et al. Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60).Leuk Res 2000 Jun;24(6):543-8.
[5] Del BinoG, Li X, Traganos F, et al. Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs. Leukemia 1994,8:281-287.
[6] Solary E, Bertrand R, Kohn KW, et al. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.Blood, 1993,81:1359.
[7] Marks DC, Davey MW, Davey RA, et al. Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line. Biochem Pharmacol , 1995 ,50(4):475-480.
[8] Ketley NJ, Allen PD, Kelsey SM, et.al. Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH)2 Vitamin D3,and Granulocyte-Macrophage Colony-Stimulating Factor, Blood, 1997,90 (11): 4578-4587
[9] Ketley NJ, Allen PD, Kelsey SM, et.al. Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints. Leukemia, 2000,14(4):620-628.
[10] Zheng M, Simon R, Kononen J, Sauter G, Mihatsch MJ, Moch H. Analysis of gene expression profiles among 3 epithelial ovarian tumor subtypes using cDNA and tissue microarrays.Ai Zheng 2004; 23: 771-776
[11] Andersen CL, Monni O, Wagner U, Kononen J, Barlund M, Bucher C, Haas P, Nocito A, Bissig H, Sauter G, Kallioniemi A. High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fl uorescence in situ hybridization to tissue microarrays. Am J Pathol 2002; 161: 73-79
[12]付劲蓉刘文励周剑锋等。急性髓系白血病细胞多药耐药相关基因的筛选。华中科技大学学报(医学版)。2005,34(6):659-665.
[13] Kononen J,Bubendorf L,Kallionie mi A,et a1.Tissue microarrays for high-throughput molecular profiling of tumor specimens[J].Nat Med,1998,4:844-847.
[14]周小鸽,张劲松,张小平等。组织芯片团。中华病理学杂志,2002, 31 (2): 70-71.
[15] Battifora H, The multitumor(sauage) tissue block:novel method for immunohistochemical antibody testing[J].Lab Invest, 1986,55:244-248.
[16]韩瑞刚,张建中,黄英武等。肺石蜡包埋组织及新鲜标本组织芯片制备方法学探讨闭。临床实验病理学杂志,2002, 18 (4): 404-408。
[17] Schraml PKononen J,Bubendorf L, et a1.Tissue microarrays for gene amplification surveys in many different tumor types[J].Clin Cancer Res,1999,5:1966-1975.
[18] Schraml PSchmerdtfeger QBurkhalter F, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAKI at llq13,5-q14 as a critical oncogene target in ovarian carcinoma[J].Ammerican J of Pathol, 2003, 163:985-992.
[19] StojAd5inovic A, Hoos A, Nissan A, et al. Parathyroid neoplasm: clinical, histopathological,and tissue microarray-based molecular analysis[J].Hum Pathol, 2003,34(1):54-64.
[20] Freier K, Joos S, Flechtemacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplification in heAd5 and neck squamous cell carcinoma [J].Cancer Res, 2003, 63(6): 1179-1182.
[21] Zaharieva BM, Simon R, Diener PA, et al. High-throughput tissue microarray analysis of llq13 gene amplification (CCND1, FGF3, FGF4, EMSI)in urinary blAd5der cancer[J].J Patho1,2003,201(4):603-608.
[22] Kang JY, Dolled FM, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met,matriptase,and hepatocyte growth factor activator inhibitor 1 in the progression of mole-egative breast cancer[J].Cancer Res,2003, 63(5):1102-1105.
[23]张杰林,方燕,黄必军等,应用组织微阵列技术分析各期鼻咽癌组织P16切.中华病理学杂志,2002,31 (2): 132-1350
[24] Chan JK, Wong CS, Ku WT, et al. Reflections on the use of controls in immunohistochemistry and proposal for application of a multitissue spring-roll control block [J].Ann Diagn Patho1,2000,4(5):329-336.
[25] Packeisen J, Buerger H, Krech R, et al. Tissue microarrays:A new approach for quality control in immunhistochemistry[J].J of Clinical Patho1,2002,55:613-615.
[26] LiH,SunY,KongQY,ZhangKL,Wan gXW ,Chen XY,Wang Q,Liu J.Combination of nucleic acid an d protein isolation with tissue array cons truction:using defined histologic regions in single frozen tissue blocks for multiple research purposes.Int,MofMed 2003;12:299-304
[27] Cui Dx,Zhan g L,Yan XJ,Zhang LX,Xu JR,GuoYH。Jin GQ。Gomez Gt Li Dt Zhao JRt Han FCI Zhang J,Hu JL,Fan DM,Gao HJ.A microarraybasedgastric carcinoma prewarning system .WorldI Gastroenterol 2005;11:1273.1282
[28] Dan HLt Zhang YL。Zhang Yt W ang YDt Lai ZS.Yan g Cui HH,JianⅥ,Geng J,Ding YQ Guo CHI Zhou DY.A novel meth od for preparation of tissue microarray.World I Gastroenterol 2004;10:579.582
[29] Lusis EA,Chicoine MR,Perry A.High throughputscreening of meningioma biomarkers using a tissuemicroarray.,Neurooncol 2005;73:219.223
[30] Sun Y,Li JY,He JS,zhou LX,Chen K.Tissuemicroarray an alysis of multiple gene expression in intestinal metaplasia,dysplasia an d carcinom a of the stom ach.Histopatholo~ 2005:46:5O5_514
[31] Kondoh N,Wakatsuki T,Ryo A,HAd5a A,et al.Identification and characterization genes associated with human hepatocellular carcinogenesis[J].Cancer Re 1999,59(19):4990-4996.
[32] Ueta T,Ikeguchi M,Hirooka Y,et al.Beta-catenin and cyclin D1 expression human hepatocellular carcinoma[J].Oncol Rep,2002,9(6):1197-1203.
[33] Yamamoto S,Tomita Y,Nakamori S,et al.Elevated expression ovalosin-containing protein(p97)in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence[J].J Clin Oncol,2003,21(3):447-452 .
[34] Chuma M,Sakamoto M,Yamazaki K,et al.Expression profiling in multistage hepatocarcinogenesis:identification of HSP70 as a molecular marker of earhepatocellular carcinoma [J].Hepatology,2003,37(1):198-207.
[35] Xu H, Tepper CG, Jones JB, Fernandez CE, Studzinski GP: 1,25-dihydroxyvitamin D3 protects HL-60 cells against apoptosis but down-regulates the expression of the Bcl-2 gene. Exp Cell Res, 1993,209:367.
[36] Del BinoG, Li X, Traganos F, et al. Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs. Leukemia 1994,8:281-287.
[37] Solary E, Bertrand R, Kohn KW, et al. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.Blood, 1993,81:1359.
[38] Marks DC, Davey MW, Davey RA, et al. Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line. Biochem Pharmacol , 1995 ,50(4):475-480.
[39]张开泰,李刚,葛世丽,等.生物素标记文库筛选与cDNA快速终末端扩增技术克隆HRNT-l新基因[J].癌症.2000, 19(9): 939942.
[40] Frohman, M. A., Dush, M. K., Martin, G. R. Rapid production of full-length cDNAsfrom rare transcripts: amplification using a single gene-specific oligonucleotide primer [J]. Proc Natl AcAd5 Sci USA. 1988, 85: 8998-9002.
[41]邬珺超,蒋滢.cDNA末端快速扩增技术的研究进展.氨基酸和生物资源.2003,25(1):2531.
[42] Loh EY, Elliotl JF, Cwila S, et al. Poly-merase chain reaction with single-sided specificity: analysis of T cell receptor d chain[J]. Science. 1989, 243: 217-220.
[43] Ohara O., Dorit R. L., Gilbert W. One-sided poly-merase chain reaction: The amplification of cDNA[J]. Proc Natl AcAd5 Sci USA. 1989, 86: 5673-5677.
[44]李关荣,鲁成,夏庆友,等.cDNA末端快速扩增技术(RACE)的优化与改良.生命科学研究.2003, 7(3):189-197.
[45] Forhman MA,Dush MK,Martin GR.Rapid production of full-length cDNAs from rare transcripts:amplification using a single gene-specific oligonucleotide prime[J].Proc Natl AcAd5 Sci USA,1988,85:8998.
[46] Miller AD5. Human gene therapy comes of age. Nature. 1992 Jun 11; 357(6378): 455-60.
[47] Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem. 1993; 62: 191-217.
[48] Graham, F. L. & Prevec, L. (1991). Methods Mol. Biol. 7, 109 128.
[49] Berkner KL. Development of Ad5enovirus vectors for the expression of heterologous genes. Biotechniques. 1988 Jul-Aug; 6(7): 616-29.
[50] Stewart PL, Fuller SD, Burnett RM. Difference imaging of Ad5enovirus: bridging the resolution gap between X-ray crystallography and electron microscopy[J]. EMBO J. 1993 Jul; 12(7): 2589-99
[51] Rekosh DM, Russell WC. Processing of the precursor to the major core polypeptide of Ad5enovirus type 5 removes a region near the amino terminus[J]. Virology. 1977 Oct 15; 82(2): 513-7
[52] Anderson CW, Young ME, Flint SJ. Characterization of the Ad5enovirus 2 virion protein, mu[J]. Virology. 1989 Oct; 172(2): 506-12
[53] Matthews DA, Russell WC. Ad5enovirus protein-protein interactions: molecular parameters governing the binding of protein VI to hexon and the activation of the Ad5enovirus 23K protease[J]. Gen Virol. 1995 Aug; 76 ( Pt 8): 1959-69
[54] Weber J. Genetic analysis of Ad5enovirus type 2 III. Temperature sensitivity of processing viral proteins[J]. Virol. 1976 Feb; 17(2): 462-71
[55] Webster A, Russell WC, Kemp GD. Characterization of the Ad5enovirus proteinase: development and use of a specific peptide assay[J]. Gen Virol. 1989 Dec; 70 ( Pt 12): 3215-23
[56] Horwitz, M. S. Fields, B. N., Knipe, D. M., Howley, P. M., Chanock, R. M., Melnick, J. L., Monath, T. P., Roizman, B., & Straus, S. E., eds. (1996) in Fields Virology (Lippincott, PhilAd5elphia)
[57] Ballay A, Levrero M, Buendia MA et al. In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human Ad5enoviruses[J]. EMBO J. 1985 Dec 30; 4(13B): 3861-5
[58] Rosenfeld MA, Siegfried W, Yoshimura K, et al. Ad5enovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo[J]. Science. 1991 Apr 19; 252(5004): 431-4
[59] Hayashi S,Ieu D,Yamii Y ,et a1.Effect of Ad5enovirus-mediated transfer of the CTI A4 IG gene in hamster-to-rat xenotransplantation.Transplantation,2005,80:494.
[60] Kanerva A,Hemminki A.Ad5enoviruses for treatment of cancer. Ann Med , 2005 , 37:33-43.
[61] Phase 2 breast cancer study shows clinical responses in 90 percent of patients treated with Introgen,s Ad5vexin therapy.Introgen Therapeu- tics,Inc.News Release,2003,6-2.
[62] Douer D. New Ad5vances in the treatment of acute promyelocytic leukemia.Int J Hematol ,2002,762:179-87.
[63] Gueddari N, MAd5oulet C, Lefebvre P, et al. Partial restoration of all trans retinoic acid (ATRA) sensitivity by compactin in ATRA-resistant leukemic cells (ATRA-R HL-60).Leuk Res 2000 Jun;24(6):543-8.
[64] Dam iani D , M ichieli M ,M ichelutti A , et a1.AntibodY binding capacity for evaluation of M DR-related proteins in acute promyelocytic leukemia;Onset versus relapse expression. Cytometry B Clin Cytom ,2004,59(1):4O-45.
[65] Degos L.The history of acute promyelocytic leukamemia.Br J Haematol,2003,122(4):539-553.
[66] Ronan Quere, Aurelie Baudet, Bruno Cassinat,et al. Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood, 2007, 10.1182.
[67] Casale F, D’Angelo V , Ad5deo R, et a1. P-glycoprotein 17O expression and function as an Ad5verse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep.2004, 12(6):1201-1207.
[68] Stromskaya TP.Rybalkina EY.Zabotina TN,et al. Influence of RARa gene on M DR1 expression and P-glycoprotein function in human leukemic cells. Cancer CeIl Int,2005,5:15.
[69] JS Moreb, D Mohuczy, D Muhoczy, et al. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol, 2007; 59(1): 127-36.
[70] Solary E, Bertrand R, Kohn KW, et al. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.Blood, 1993,81:1359.
[71] Marks DC, Davey MW, Davey RA, et al. Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line. Biochem Pharmacol , 1995 ,50(4):475-480.
[72] Palozza P, Serini S, Torsello A, et al. Regulation of cell cycle progression and apoptosis by beta-carotene in undifferentiated and differentiated HL-60 leukemia cells: possible involvement of a redox mechanism. Int J Cancer,2002, 97(5):593-600.
[73] Brown G, Drayson MT, Durham J, et al. HL60 cells halted in G1 or S phase differentiate normally. Exp Cell Res ,2002 ,281(1):28-38.
[74] Ketley NJ, Allen PD, Kelsey SM, et.al. Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH)2 Vitamin D3,and Granulocyte-Macrophage Colony-Stimulating Factor, Blood, 1997,90 (11): 4578-4587.
[1]. Okuno M, Kojima S, Matsushima-Nishiwaki R, et al. Rrtinoids in cancer chemoprevention. Curr Cancer Drug Targets, 2004,4(3): 285-298.
[2]. Candoni A, Damiani D, Michelutti A, et al. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in Ad5ult patients with acute promyelocytic leukemia. Eur J Haematol, 2003,71(1):1-8.
[3]. Ronan Quere, Aurelie Baudet, Bruno Cassinat,et al. Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood, 2007, 109(10): 4450-4460.
[4].王玮,岑建农,李建勇,等,急性白血病中MDR1、MRP和BCL-2表达及其临床意义.中国肿瘤临床, 2003,30(7):470-473.
[5]. Casale F, D’Angelo V, Ad5deo R ,et a1. P-glycoprotein 170 expression and function as an Ad5verse independent prognostic factor in childhood acute lymphoblastic leukemia.Oncol Rep.2004, 12(6):1201-1207.
[6]. Stromskaya TP. Rybalkina EY .Zabotina TN ,et al. Influence of RARa gene on MDR1 expression and P-glycoprotein function in human leukemic cells. Cancer CeIl Int , 2005,5:15.
[7]. Takeshita, A, Shigeno, K, Shinjo K, et al。All-trans retinoic acid (ATRA) differentiates acute promyelocytic leukemia cells independently of P-glycoprotein (P-gp) related multidrug resistance.Leuk-Lymphoma. 2001 ,42(4): 739-746.
[8]. Galimberti S, Testi R, Guerrini F, et al.: The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia. J Chemother 2003, 15(4): 374-379.
[9]. Van den Heuvel-Eibrink MM, Wiemer EA, Prins A, et al. Increased expression of breast cancer resistance in relapsed or refractory acute myeloid leukemia. Leukemia, 2002, 16(5): 833-839.
[10]. Herman Burger, Hans van Tol, Antonius W. M. et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 2004, 104(9):2940-2942.
[11].任金海,杜行严,郭晓楠,等,急性白血病细胞的乳腺癌耐药蛋白基因表达与化疗耐药的关系.中国实验血液学杂志,2004,12(1):55-58.
[12]. Schaich M, Koch R, Soucek S, et al .A sensitive model for prediction of relapse in Ad5ult acute myeloid leukaemia with t (8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis. Br J Haematol 2004, 125(4): 477-479.
[13]. Avivi, Irit; Rowe, Jacob M。Prognostic factors in acute myeloid leukemia . Current Opinion on Hematology, 2005, 12 (1) :62-67.
[14]. Imaizumi M, Suzuki H, Yoshinari M, et al. Mutations in the E-Dornain of RARαprotein of the PML-RARαchimeric Gene may confer clinicl resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood, 1998, 92(2):374-382.
[15]. Gaboli M, Candini D, Delval, et al. acute promyelocytic leukemia as a model forcross-talk between interferon and retinoic acid phhways: from molecular biology to clinical applications. Leuk lymphoma, 1998 , 30 (1-2): 11-22.
[16]. Huan SY, Yang CH, Chen YC. Arsenic trioxide therapy for ielapsed acute promyelocytic leukemia:an useful salvage therapy. Leuk lymphoma, 2000,38 (3-4) : 283-293.
[17]. Zwiebel JA, New agents for acute promyelocytic leukemia. Leukemia, 2000,14(3): 488-490.
[18]. Ikezoe T, Daar ES, Hisatake J, et al. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood, 2000,96(10): 3553-3559.
[1]. Hocking DC, Kowalski K. A cryptic fragment from fibronectin’s III1 aodule localizes to lipid rafts and stimulates cell growth and contractility. Cell Biol,2002,158(1):175.
[2]. Finnemann S. C. and Silverstein R. L.Differential Roles of CD36 and {alpha}v{beta}5 Integrin in Photoreceptor Phagocytosis by the Retinal Pigment Epithelium.J. Exp. Med, 2001, 194(9): 1289 - 1298.
[3]. Bocquie AA, Potss JR, Pickfored AR, et al. Solution structure of a pair ofmodules from the gelaoin-binding domain of fibronectin. Structure Fold Des, 1999,7(12):1451.
[4]. Huesca M, Sun Q, Peralta R, et al. Synthetic peptide immunogens elicit polyclonal and monoclonal antibodies specific for linear epitopes in the D motifs of Staphylococcus aureus fibronectin-binding protein, which are composed of amino acids that are essential for fibronectin binding. Infect Immum,2000,68 (3):1156.
[5]. Yair Gazitt, Cagla Akay. Mobilization of Myeloma Cells Involves SDF-1/CXCR4 Signaling and Downregulation of VLA-4. Stem Cells, 2004,22(1):65-73.
[6]. Orschell-Traycoff, Anna Jetmore and Edward F. Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34+ cells transplanted into conditioned NOD/SCID recipients.Blood, 2002,99(3): 1585 - 1593.
[7]. Christina H, Diana D, Gunnar M, Jochen G, et al .Expression and Function of Homing-Essential Molecules and Enhanced In Vivo Homing Ability of Human Peripheral Blood-Derived Hematopoietic Progenitor Cells after Stimulation with Stem Cell Factor.Stem cells, 2004,22(7):580-589
[8]. Foguenne J, Huygen S, Greimers R, et al. Modulation of homing properties of primitive progenitor cells generated by ex vivo expansion. Haematologica,2005 ,90(4):445-51.
[9]. Maria A,Hui Wang,Megan Sykes,et al.Role of VLA-4 and VLA-5 in ex vivo maintenance of human and pig hematopoiesis in human stroma-supported long-term cultures.Experimental Hematology,2005,33(1):363-370.
[10]. Shain KH, Dalton WS.Cell Ad5hesion is a key determinant in de novo multidrug resisrance(MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther, 2001,1(1):69-78.
[11]. Holt RU, Baykov V, Ro TB, et al. Human myeloma cells Ad5here to fibronectin in response to hepatocyte growth factor. Haematologica, 2005 ,90(4):479-488..
[12]. Hazlehurst LA, Damiano JS, Buyyksal I, et al. Ad5hesion to fibronectin via betal integrins reglates p27kipl levels andcontributes to cell Ad5hesion mediated drug resistance (CAM-DR). Oncogene, 2000,19(38):4319-4327.
[13]. Landowski TH, Olashaw NE, Agrawal D, et al. Cell Ad5hesion mediated drugresistance (CAM-DR) is associated with activation of NF-kappa B(RelB/p50) in myeloma cells. Oncogene, 2003,22(16):2417-2421.
[14]. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.Leukemia, 2003,17(6):1175-1182.
[15]. de la Fuente MT, Casanova B,Moyano JV, et al. Engagement of alpha4betal integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabne. J Leukoc Biol, 2002,71(3):495-502.
[16]. Matsunaga T, Takemoro N, Sato T, et al. Interaction between leukemic VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med,2003,9(9):1158-1165.
[17]. Chauhan D, G. Li, K. Podar, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.Blood, 2004,103(8): 3158 - 3166.
[18]. Shain KH, Landowski TH, Dalton WS. Ad5hesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistances to CD95 induced apoptosis in hematopoietic cancer cell lines. J Immunol, 2002,17(6):2544-2553.
[19]. Nefedova Y, P. Cheng, M. Alsina, et al. and D.I.GabrilovichInvolvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines.Blood,2004,103(9): 3503 - 3510.
[20]. Heyu Ni , Cecile VD, Sangeetha S, et al. Persistence of platelet thrombus fomation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Inves,2001(8),106:385-392.
[21]. An G, Dong N, Shao B, Zhu M, Ruan C. Preparation and characterization of a single chain antibody fragment of mAb SZ-21 against platelets GPIIIa。Zhonghua Xue Ye Xue Za Zhi, 2002 ,23(9):480-2.